Released Mar 7, 2024, before the open
10-K filed Mar 7, 2024, 67 days after period end · 0001628280-24-009539
Q4 2023 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$5.77M$5.77M derived+37.9% vs Q4 2022−67.0% vs Q3 2023
Net Income-$24.11M-$24.11M derivedN/M vs Q4 2022N/M vs Q3 2023
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$25,458,000N/M
Operating Cash Flowderived-$27,541,000N/M
Free Cash Flowderived-$27,578,000N/M
Margins · derived
Operating margin-441.3%+320.8 pt vs Q4 2022
Net margin-417.9%+272.5 pt vs Q4 2022
What the release said
The release
Same quarter
| Metric | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures | Q4 2020dderived from reported figures |
|---|---|---|---|---|
| Revenue | $5.77M | $4.18M | $713.00K | $251.00K |
| Net Income | -$24.11M | -$28.89M | -$29.14M | -$20.76M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Foghorn Therapeutics Inc. · CIK 1822462 · Engraved from SEC EDGAR